A detailed history of Relyea Zuckerberg Hanson LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Relyea Zuckerberg Hanson LLC holds 10,188 shares of ABBV stock, worth $1.79 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
10,188
Previous 9,971 2.18%
Holding current value
$1.79 Million
Previous $1.71 Million 17.6%
% of portfolio
0.31%
Previous 0.29%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$163.84 - $199.33 $35,553 - $43,254
217 Added 2.18%
10,188 $2.01 Million
Q2 2024

Oct 31, 2024

BUY
$154.79 - $180.76 $20,896 - $24,402
135 Added 1.37%
9,971 $1.71 Million
Q2 2024

Jul 17, 2024

BUY
$154.79 - $180.76 $20,896 - $24,402
135 Added 1.37%
9,971 $1.71 Million
Q1 2024

Oct 31, 2024

BUY
$159.82 - $182.1 $85,343 - $97,241
534 Added 5.74%
9,836 $1.79 Million
Q1 2024

Apr 22, 2024

BUY
$159.82 - $182.1 $85,343 - $97,241
534 Added 5.74%
9,836 $1.79 Million
Q4 2023

Oct 31, 2024

BUY
$137.6 - $154.97 $34,124 - $38,432
248 Added 2.74%
9,302 $1.44 Million
Q4 2023

Jan 18, 2024

BUY
$137.6 - $154.97 $34,124 - $38,432
248 Added 2.74%
9,302 $1.44 Million
Q3 2023

Oct 31, 2024

SELL
$133.59 - $154.65 $151,491 - $175,373
-1,134 Reduced 11.13%
9,054 $1.35 Million
Q3 2023

Oct 16, 2023

BUY
$133.59 - $154.65 $94,047 - $108,873
704 Added 8.43%
9,054 $1.35 Million
Q2 2023

Jul 17, 2023

BUY
$132.51 - $164.9 $65,592 - $81,625
495 Added 6.3%
8,350 $1.12 Million
Q1 2023

Apr 18, 2023

BUY
$144.61 - $166.54 $140,127 - $161,377
969 Added 14.07%
7,855 $1.25 Million
Q4 2022

Jan 18, 2023

BUY
$138.31 - $165.87 $130,979 - $157,078
947 Added 15.95%
6,886 $0
Q3 2022

Nov 02, 2022

BUY
$134.21 - $153.93 $34,760 - $39,867
259 Added 4.56%
5,939 $797,000
Q2 2022

Jul 18, 2022

BUY
$137.62 - $174.96 $6,330 - $8,048
46 Added 0.82%
5,680 $870,000
Q1 2022

Apr 19, 2022

SELL
$131.98 - $163.75 $15,705 - $19,486
-119 Reduced 2.07%
5,634 $896,000
Q4 2021

Jan 27, 2022

BUY
$107.43 - $135.93 $111,190 - $140,687
1,035 Added 21.94%
5,753 $759,000
Q4 2021

Jan 14, 2022

SELL
$107.43 - $135.93 $50,384 - $63,751
-469 Reduced 9.04%
4,718 $506,000
Q3 2021

Oct 22, 2021

BUY
$106.4 - $120.78 $15,321 - $17,392
144 Added 2.86%
5,187 $560,000
Q2 2021

Jul 23, 2021

BUY
$105.21 - $117.21 $12,835 - $14,299
122 Added 2.48%
5,043 $568,000
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $20,766 - $22,861
203 Added 4.3%
4,921 $548,000
Q4 2020

Jan 28, 2021

SELL
$80.49 - $108.67 $804 - $1,086
-10 Reduced 0.21%
4,718 $506,000
Q3 2020

Oct 16, 2020

SELL
$85.91 - $100.83 $3,436 - $4,033
-40 Reduced 0.84%
4,728 $414,000
Q4 2019

Jan 15, 2020

BUY
$72.13 - $90.25 $343,915 - $430,312
4,768 New
4,768 $422,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Relyea Zuckerberg Hanson LLC Portfolio

Follow Relyea Zuckerberg Hanson LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Relyea Zuckerberg Hanson LLC, based on Form 13F filings with the SEC.

News

Stay updated on Relyea Zuckerberg Hanson LLC with notifications on news.